Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 44,200 shares, a growth of 9.4% from the October 15th total of 40,400 shares. Based on an average daily volume of 31,500 shares, the short-interest ratio is currently 1.4 days.

Entera Bio Stock Down 4.0 %

ENTX stock opened at $1.66 on Tuesday. Entera Bio has a 52 week low of $0.52 and a 52 week high of $3.35. The firm has a 50 day moving average of $1.85 and a 200 day moving average of $1.91. The stock has a market capitalization of $59.40 million, a PE ratio of -6.38 and a beta of 1.58.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research note on Monday, November 11th.

Institutional Trading of Entera Bio

Several institutional investors and hedge funds have recently bought and sold shares of ENTX. Virtu Financial LLC acquired a new stake in Entera Bio during the 1st quarter valued at approximately $37,000. Signature Estate & Investment Advisors LLC acquired a new stake in Entera Bio during the 3rd quarter valued at approximately $90,000. Finally, Parkman Healthcare Partners LLC lifted its stake in Entera Bio by 2.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after acquiring an additional 9,558 shares during the period. 14.11% of the stock is currently owned by institutional investors and hedge funds.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.